Predictors of Heightened Platelet Reactivity Despite Dual-Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention

Pre-Procedural Platelet Reactivity After Clopidogrel Loading in Korean Patients Undergoing Scheduled Percutaneous Coronary Intervention

“…Furthermore, many studies have demonstrated that carriers of the CYP2C19 2 variant allele have a higher risk of adverse cardiovascular events in Caucasian patients with ACS or undergoing PCI [29][30][31][32] . Price et al demonstrated the independent contribution of ethnicity to HPPR 33) . Recent studies showed that the Korean population has a higher prevalence of the CYP2C19 variant allele (60% vs. 25 − 30% in Caucasians), with carriage of the CYP2C19 3 mutant allele 16,17) .…”

Preinterventional Clopidogrel Response Variability for Coil Embolization of Intracranial Aneurysms: Clinical Implications

“…Several studies in the field of cardiology demonstrated that high PRU values were associated with increased periprocedural myocardial infarction as well as mortality after percutaneous coronary intervention. 24,31 Regarding the mode of CPG administration, chronic use (Ն7 days) provided benefit in reducing platelet reactivity (Table 4). In our series, the chronic users had some reasons for the CPG prescription, including histories of previous cerebral infarction or coronary artery disease with or without percutaneous coronary intervention performed; otherwise we did give CPG the day before the coil embolization at the time of admission.…”

“…23 Residual platelet reactivity on CPG therapy was measured by using the VerifyNow P2Y12 assay (Accumetrics), a turbidimetricbased optical detection system that measures platelet aggregation. 23,24 This system measures platelet aggregation as an increase in light transmittance and produces 3 values, including BASE, PRU, and percentage inhibition. BASE is a platelet reaction unit measured after stimulation with an isothrombin-receptor-activating peptide and serves as an estimate of baseline platelet reactivity.…”

Resistência ao clopidogrel: prevalência e variáveis associadas

“…Diabetes and glucose control determine the predictors of clopidogrel resistance in most studies 20,21 . Within the diabetic population, some studies show that glycemic control, in most of them measured by glycosylated hemoglobin, has an even more deleterious effect on the antiplatelet therapy profile than the disease itself 22,23 .…”